Genitourinary cancer (GUC) represents more than one fifth of all human cancers. This makes the development of approaches to its early diagnosis an important task of modern biomedicine. Circulating microRNAs, short (17–25 nucleotides) non-coding RNA molecules found in human biological fluids and performing a regulatory role in the cell, are considered as promising diagnostic and prognostic biomarkers of cancers, including GUC. In this review we have considered the current state of research aimed at assessing microRNAs as biomarkers of such human GUC types as malignant tumors of the bladder, kidney, prostate, testicles, ovaries, and cervix. A special attention has been paid to studies devoted to the identification of microRNAs in urine as a surrogate “liquid biopsy” that may provide the simplest and cheapest approach to mass non-invasive screening of human GUC. The use of microRNA panels instead of single types of microRNA generally leads to higher sensitivity and specificity of the developed diagnostic tests. However, to date, work on the microRNAs assessment as biomarkers of human GUC is still of a research nature, and the further introduction of diagnostic tests based on microRNAs into practice requires successful clinical trials.
Download PDF:
Keywords: cancer, human genitourinary system, microRNA, diagnostic markers
Citation:
Kugaevskaya E.V., Timoshenko O.S., Gureeva T.A., Radko S.P., Lisitsa A.V. (2024) MicroRNAs as promising diagnostic and prognostic markers for the human genitourinary cancer. Biomeditsinskaya Khimiya, 70(4), 191-205.
Kugaevskaya E.V. et al. MicroRNAs as promising diagnostic and prognostic markers for the human genitourinary cancer // Biomeditsinskaya Khimiya. - 2024. - V. 70. -N 4. - P. 191-205.
Kugaevskaya E.V. et al., "MicroRNAs as promising diagnostic and prognostic markers for the human genitourinary cancer." Biomeditsinskaya Khimiya 70.4 (2024): 191-205.
Kugaevskaya, E. V., Timoshenko, O. S., Gureeva, T. A., Radko, S. P., Lisitsa, A. V. (2024). MicroRNAs as promising diagnostic and prognostic markers for the human genitourinary cancer. Biomeditsinskaya Khimiya, 70(4), 191-205.
References
Bellmunt J., Orsola A., Leow J.J., Wiegel T., de Santis M., Horwich A. (2014) Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 25(Suppl 3), iii40–iii48. CrossRef Scholar google search
Parker C., Gillessen S., Heidenreich A., Horwich A. (2015) Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 26, 69–77. CrossRef Scholar google search
Marth C., Landoni F., Mahner S., McCormack M., Gonzalez-Martin A., Colombo N. (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 28(Suppl 4), 72–83. CrossRef Scholar google search
Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C. (2013) ESMO Guidelines Working Group Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 24(Suppl 6), 33–38. CrossRef Scholar google search
Ray-Coquard I., Morice P., Lorusso D., Prat J., Oaknin A., Pautier P., Colombo N. (2018) ESMO Guidelines Committee Non-epithelial Ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 29(Suppl 4), 1–18. CrossRef Scholar google search
Escudier B., Porta C., Schmidinger M., Rioux-Leclercq N., Bex A., Khoo V., Grünwald V., Gillessen S., Horwich A. (2019) ESMO Guidelines Committee Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 30(5), 706–720. CrossRef Scholar google search
Colombo N., Sessa C., du Bois A., Ledermann J., McCluggage W.G., McNeish I., Morice P., Pignata S., Ray-Coquard I., Vergote I., Baert T., Belaroussi I., Dashora A., Olbrecht S., Planchamp F., Querleu D. (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced
